A carregar...
Cost-Utility Analysis of Lurasidone Versus Aripiprazole in Adults with Schizophrenia
BACKGROUND: In 2014, lurasidone, an atypical antipsychotic, was approved for the treatment of schizophrenia in adults. It is an alternative treatment option to aripiprazole, and when compared with aripiprazole, lurasidone was associated with improved symptom reduction and reduced risk of weight gain...
Na minha lista:
| Publicado no: | Pharmacoeconomics |
|---|---|
| Main Authors: | , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Springer International Publishing
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4901121/ https://ncbi.nlm.nih.gov/pubmed/27067724 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-016-0405-0 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|